Tibet AIM Pharm. Inc. (SHE:002826)

Tibet AIM Pharm. Revenue

Tibet AIM Pharm. had revenue of 202.45M CNY in the quarter ending September 30, 2026, with 14.03% growth. This brings the company's total for the last twelve months to 709.36M, up 12.95% year-over-year. In the year 2025, Tibet AIM Pharm. had annual revenue of 636.27M, down -2.39%. That makes Tibet AIM Pharm. the 22,225th largest company in the world by revenue and 4,064th in China.

• Revenue (ttm): 709.36M
• Revenue Growth: +12.95%
• P/S Ratio: 3.92
• Revenue / Employee: 1.75M
• Employees: 405
• Market Cap: 2.78B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Drug Sales 635.62M 99.7%
• Others 1.75M 0.3%

By Geography

Chart

• Southwest 294.46M 46.3%
• North China 137.45M 21.6%
• East China 120.54M 18.9%
• Northwest 63.40M 10.0%
• Northeast 20.41M 3.2%

Fiscal year ended Dec 31, 2025 See the full Tibet AIM Pharm. breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	636.27M	-15.61M	-2.39%
Dec 31, 2024	651.88M	-15.16M	-2.27%
Dec 31, 2023	667.04M	-189.70M	-22.14%
Jan 1, 2023	856.73M	131.28M	18.10%
Jan 1, 2022	725.46M	122.84M	20.38%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 13, 2026

Data Sources Report a data error